Empower your investment journey with knowledge. Subscribe to NAOS News & Insights.
By subscribing you consent to NAOS using your personal information in accordance with its Privacy Policy, a copy of which is available here.
By subscribing you consent to NAOS using your personal information in accordance with its Privacy Policy, a copy of which is available here.
We are pleased to share the NAOS Quarterly Investment Report for Q3 FY26, which provides in-depth commentary on the current market and several core investments that had notable events during Q3.
This report reflects on a quarter shaped by external macro events and heightened market uncertainty, including a sharp de-rating across ASX-listed software businesses amid the rapid emergence of AI. It provides detailed commentary on several notable portfolio developments, including PharmX Technologies' strategic alliance with Sigma Healthcare, significant milestones at unlisted investment Firmus Technologies, and a closer look at recent investment SomnoMed and the evolving sleep apnoea market.
By submitting your details, you consent to NAOS and the Company using your personal information in accordance with their Privacy Policies, copies of which are available here.
Join our investment community. Be the first to receive NAOS News, Insights and Invitations.
